| __timestamp | Ligand Pharmaceuticals Incorporated | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 5758000 |
| Thursday, January 1, 2015 | 5807000 | 8423000 |
| Friday, January 1, 2016 | 5571000 | 11986000 |
| Sunday, January 1, 2017 | 5366000 | 15215000 |
| Monday, January 1, 2018 | 6337000 | 15356000 |
| Tuesday, January 1, 2019 | 11347000 | 16660000 |
| Wednesday, January 1, 2020 | 30419000 | 52459000 |
| Friday, January 1, 2021 | 62176000 | 75061000 |
| Saturday, January 1, 2022 | 52827000 | 87221000 |
| Sunday, January 1, 2023 | 35049000 | 83779000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue. Ligand's cost of revenue surged by over 580% from 2014 to 2021, peaking in 2021 before a slight decline. In contrast, Supernus exhibited a steady increase, with a remarkable 1,350% rise over the same period, reaching its zenith in 2022. This divergence highlights Ligand's fluctuating cost management strategies compared to Supernus's consistent growth approach. Such insights are vital for investors and stakeholders aiming to navigate the competitive landscape of the pharmaceutical sector. As the industry continues to innovate, monitoring these financial metrics will be key to understanding the underlying business strategies and market positioning of these companies.
Cost of Revenue Trends: Johnson & Johnson vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: AstraZeneca PLC and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Novartis AG vs Ligand Pharmaceuticals Incorporated
Takeda Pharmaceutical Company Limited vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Incyte Corporation vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated
Xenon Pharmaceuticals Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down MorphoSys AG and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and MiMedx Group, Inc.